The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease

被引:0
|
作者
Acencio, Marcio Luis [1 ]
Ostaszewski, Marek [1 ,2 ]
Mazein, Alexander [1 ]
Rosenstiel, Philip [3 ,4 ]
Aden, Konrad [3 ,4 ,5 ]
Mishra, Neha [3 ,4 ]
Andersen, Vibeke [6 ,7 ]
Sidiropoulos, Prodromos [8 ,9 ]
Banos, Aggelos [10 ,11 ]
Filia, Anastasia [10 ,11 ]
Rahmouni, Souad [12 ]
Finckh, Axel [13 ,14 ]
Gu, Wei [1 ,2 ]
Schneider, Reinhard [1 ,2 ]
Satagopam, Venkata [1 ,2 ]
机构
[1] Univ Luxembourg, Luxembourg Ctr Syst Biomed, Esch Sur Alzette, Luxembourg
[2] ELIXIR Luxembourg, Esch Sur Alzette, Luxembourg
[3] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany
[4] Univ Med Ctr Schleswig Holstein, Kiel, Germany
[5] Univ Med Ctr Schleswig Holstein UKSH, Dept Internal Med 1, Kiel, Germany
[6] Univ Hosp Southern Denmark, Inst Reg Hlth Res, Diagnost & Clin Res Unit, Aabenraa, Denmark
[7] Univ Southern Denmark, Inst Mol Med, Odense, Denmark
[8] Univ Crete, Med Sch, Rheumatol & Clin Immunol, Iraklion, Greece
[9] Fdn Res & Technol IMBB FORTH, Inst Mol Biol & Biotechnol, Lab Rheumatol Autoimmun & Inflammat, Iraklion, Greece
[10] Biomed Res Fdn Acad Athens, Autoimmun & Inflammat Lab, Athens, Greece
[11] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Lab Mol Hematol, Alexandroupolis, Greece
[12] Univ Liege, GIGA Inst, Unit Anim Genom, Liege, Belgium
[13] Geneva Univ Hosp HUG, Rheumatol Div, Geneva, Switzerland
[14] Univ Geneva UNIGE, Geneva Ctr Inflammat Res GCIR, Geneva, Switzerland
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
欧盟地平线“2020”;
关键词
inflammatory bowel disease; rheumatoid arthritis; systemic lupus erythematosus; molecular mechanisms; curation; pathway biology; systems biology; REGULATORY T-CELL; TNF-ALPHA; DIFFERENTIATION; TOLERANCE; PHOSPHORYLATION; ANTAGONISTS; BIOMARKERS; COLITIS; SIGNALS; NETWORK;
D O I
10.3389/fimmu.2023.1257321
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic inflammatory diseases (CIDs), including inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are thought to emerge from an impaired complex network of inter- and intracellular biochemical interactions among several proteins and small chemical compounds under strong influence of genetic and environmental factors. CIDs are characterised by shared and disease-specific processes, which is reflected by partially overlapping genetic risk maps and pathogenic cells (e.g., T cells). Their pathogenesis involves a plethora of intracellular pathways. The translation of the research findings on CIDs molecular mechanisms into effective treatments is challenging and may explain the low remission rates despite modern targeted therapies. Modelling CID-related causal interactions as networks allows us to tackle the complexity at a systems level and improve our understanding of the interplay of key pathways. Here we report the construction, description, and initial applications of the SYSCID map (https://syscid.elixir-luxembourg.org/), a mechanistic causal interaction network covering the molecular crosstalk between IBD, RA and SLE. We demonstrate that the map serves as an interactive, graphical review of IBD, RA and SLE molecular mechanisms, and helps to understand the complexity of omics data. Examples of such application are illustrated using transcriptome data from time-series gene expression profiles following anti-TNF treatment and data from genome-wide associations studies that enable us to suggest potential effects to altered pathways and propose possible mechanistic biomarkers of treatment response.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] The shared circulating diagnostic biomarkers and molecular mechanisms of systemic lupus erythematosus and inflammatory bowel disease
    Sun, Hao-Wen
    Zhang, Xin
    Shen, Cong-Cong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] Systemic lupus erythematosus and inflammatory bowel disease
    Nitzan, O.
    Elias, M.
    Saliba, W. R.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2006, 17 (05) : 313 - 318
  • [3] Co-occurrences of rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus in inflammatory bowel disease patients
    Yan, S
    Robinson, D
    Eisenberg, D
    Hackett, M
    Renahan, KE
    Bala, M
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S299 - S299
  • [4] Thyroid disease in systemic lupus erythematosus and rheumatoid arthritis
    Chan, ATY
    Al-Saffar, Z
    Bucknall, RC
    RHEUMATOLOGY, 2001, 40 (03) : 353 - 354
  • [5] Does inflammatory bowel disease coexist with systemic lupus erythematosus?
    Shor, Dana Ben-Ami
    Dahan, Shani
    Comaneshter, Doron
    Cohen, Arnon D.
    Amital, Howard
    AUTOIMMUNITY REVIEWS, 2016, 15 (11) : 1034 - 1037
  • [6] The role of FcγRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus
    Sardjono, CT
    Mottram, PL
    Hogarth, PM
    IMMUNOLOGY AND CELL BIOLOGY, 2003, 81 (05): : 374 - 381
  • [7] Neuropsychiatric disease in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
    Hanly, JG
    McCurdy, G
    Fougere, L
    Douglas, JA
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S195 - S195
  • [8] Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
    Dey, Mrinalini
    Parodis, Ioannis
    Nikiphorou, Elena
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [9] Premature atherosclerotic disease in systemic lupus erythematosus - role of inflammatory mechanisms
    Rhew, EY
    Ramsey-Goldman, R
    AUTOIMMUNITY REVIEWS, 2006, 5 (02) : 101 - 105
  • [10] FIBRONECTIN AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
    Emelyanova, O.
    Trofimenko, A.
    Rusanova, O.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S196 - S196